Identification of differential polypharmacology between the PARP inhibitor rucaparib and its major metabolite
Hu, H.; Serra, C.; Llebaria, A.; Antolin, A. A.
Show abstract
The (poly)pharmacology of drug metabolites is seldom comprehensively characterized in drug discovery and development. However, some drug metabolites can reach high plasma concentrations and display relevant in vivo activity, which can be distinct from its parent drug. Here, we use computational and experimental methods to comprehensively characterise the kinase polypharmacology of M324, the major metabolite of the FDA-approved PARP inhibitor rucaparib. We experimentally demonstrate that M324 displays a distinct in vitro kinome profile from its parent drug, characterized by potent in vitro inhibition of GSK3A and PLK2 at clinically-relevant concentrations. These confirmed kinase activities of M324 could have potential implications for the efficacy and safety of rucaparib and therefore warrant further clinical investigation. The study reported here highlights the importance of thoroughly characterizing the activity of significant drug metabolites to better understanding drug responses in the clinic and maximally exploit the current drug arsenal in personalized and precision medicine.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2 93%
- Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19 93%
- Machine learning enables accurate and rapid prediction of active molecules against breast cancer cells 92%
Similar papers in this journal
- Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2 95%
- Fragment Screening and Structure-Guided Development of Heparanase Inhibitors Reveals Orthosteric and Allosteric Inhibition 94%
- AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.